A Phase 3 interventional study of Bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 36 sites in 18 countries. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 12th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 3 Months to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 37 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 9 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 30th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2011, is one of 31 in phase 3, and was the 28th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
Drug: Bosentan
Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
Drug: Bosentan
Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
Also known as: ACT-050088
Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation
This is the total number of subjects with at least one adverse event (serious or not serious) whether or not causally related to the study drug and presented cumulatively in the FUTURE 3 and FUTURE 3 Extension study. NOTE: FUTURE 3 extension study was exploratory and no primary efficacy and safety endpoints were defined in the protocol. So, this safety outcome measure was selected and reported as primary endpoint here.
Time frame: Up to 62 weeks in average
Change From Baseline up to 12 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)
The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
Time frame: At Month 12
Change From Baseline up to 18 Months of Study Treatment in the World Health Organization Functional Classification (WHO FC)
The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
Time frame: At Month 18
Change From Baseline up to 12 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)
The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
Time frame: At Month 12
Change From Baseline up to 18 Months of Study Treatment in the Global Clinical Impression Scale (GCIS)
The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
Time frame: At Month 18
Number of Patients With Pulmonary Arterial Hypertension (PAH) Worsening Components up to the Last Day of Treatment + 7 Days
Number of patients with at least one PAH-worsening component (death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH, new/worsening right heart failure) reported cumulatively over FUTURE 3 core and extension study.
Time frame: Up to 62 weeks in average
Pulmonary Arterial Hypertension (PAH) Progression up to End of Treatment + 7 Days
PAH progression was defined by time elapsed from the first study drug administration in the FUTURE core study to the day of the first occurrence of any of the following PAH worsening events: death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH or new / worsening right heart failure. Subjects without a PAH worsening event were censored at EOT + 7 days. PAH progression was estimated by Kaplan-Meier methodology and expressed by the percentage of participants free of events at different time points.
Time frame: From baseline to Month 18
Overall Survival
Overall survival was defined as the time elapsed between the first study drug administration and death (any cause) up to end of study (Month 18 survival follow-up), regardless of whether the patient was on study treatment. Patients who died, regardless of the cause of death, were considered to have had an event. Patients last known to have been alive were censored on their date of last contact. Percentage of participants without death at different time points was estimated using Kaplan-Meier methodology.
Time frame: From baseline to month 18
Exceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Percentage of participants with AEs leading to premature discontinuation of study drug were reported.
Time frame: Up to 3 years and 4 months
EUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: From 7 up to 60 days after permanent discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Deaths
Percentage of participants with deaths were reported.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Adverse Events of Special Interest (AESI)
Percentage of participants with AESI including liver abnormalities and anemia were reported.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug
Percentage of participants with treatment-emergent marked laboratory abnormalities were reported.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Liver Function Abnormalities
Percentage of participants with liver function abnormalities: Alanine aminotransferase (ALT) greater than (\>)3\*upper limit of normal (ULN), ALT/aspartate aminotransferase (AST) \>3\*ULN, ALT /AST \>3\*ULN and less than or equal to (\<=) 5\*ULN, ALT/AST \>5\*ULN and \<=8\*ULN, ALT/AST \>8\*ULN and ALT/AST \>3\*ULN, total bilirubin \>2\*ULN and alkaline phosphatase (ALP) \<=2\*ULN were reported.
Time frame: Up to 7 days after discontinuation of study drug (up to 3 years and 4 months)
EUTP: Percentage of Participants With Any Time Occurrence of Hemoglobin <=10 Gram Per Deciliter (g/dL) and <=8g/dL Between Baseline and up to 7 Days After End of Treatment (EOT)
Percentage of participants with any time occurrence of hemoglobin (Hgb) less than or equal to (\<=) 10 g/dL and 8 g/dL between baseline and up to the last day of treatment + 7 days during EUTP were reported. Here "N" (number of subjects analyzed) signifies subjects who were evaluable for this outcome measure.
Time frame: Baseline, up to 7 days after end of treatment (up to 3 years and 4 months)
Participants in this 1-year extension study were pediatric patients who completed the 6-month randomized open-label core study AC-052-373. In addition, patients were required to have tolerated study treatment during the FUTURE 3 core study and were considered by the investigator to benefit from continued bosentan treatment.
| Milestone | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|---|---|
| Started | 33 | 31 | 0 |
| Enrolled in future 3 extension | 31 | 27 | 0 |
| Completed | 23 | 22 | 0 |
| Not completed | 10 | 9 | 0 |
| Withdrew: Adverse event | 8 | 6 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Other (pah not the main etiology of ph) | 0 | 2 | 0 |
| Withdrew: Other (administrative reason) | 1 | 0 | 0 |
| Milestone | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|---|---|
| Started | 0 | 0 | 10 |
| Completed | 0 | 0 | 4 |
| Not completed | 0 | 0 | 6 |
| Withdrew: Administrative decision | 0 | 0 | 1 |
| Withdrew: Ongoing at the cut-off date of 19 nov 2019 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
This is the total number of subjects with at least one adverse event (serious or not serious) whether or not causally related to the study drug and presented cumulatively in the FUTURE 3 and FUTURE 3 Extension study. NOTE: FUTURE 3 extension study was exploratory and no primary efficacy and safety endpoints were defined in the protocol. So, this safety outcome measure was selected and reported as primary endpoint here.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation | 29 | 26 |
The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Stable WHO FC | 22 | 25 |
| Improved WHO FC | 7 | 3 |
| Worsened WHO FC | 4 | 3 |
The WHO FC indicates the severity of Pulmonary Arterial Hypertension: class I (none) to class IV (most severe). Changes from baseline to month 12 and month 18 of treatment with bosentan included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or no change/stable (same FC at baseline and at the post-baseline time point). Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Stable WHO FC | 25 | 25 |
| Improved WHO FC | 3 | 3 |
| Worsened WHO FC | 5 | 3 |
The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Assessment by Physician — Stable | 16 | 16 |
| Assessment by Physician — Improved | 10 | 6 |
| Assessment by Physician — Worsened | 2 | 1 |
| Assessment by Parents/Legal representative — Stable | 16 | 12 |
| Assessment by Parents/Legal representative — Improved | 9 | 11 |
| Assessment by Parents/Legal representative — Worsened | 3 | 0 |
The GCIS is a scale used to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad", and "Very Bad"). Rating was performed independently by the physician and parents or legal representatives. Baseline was defined as the last valid assessment performed prior to first study drug intake in the FUTURE 3 core study.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Assessment by Physician — Stable | 9 | 12 |
| Assessment by Physician — Improved | 6 | 5 |
| Assessment by Physician — Worsened | 4 | 1 |
| Assessment by Parents/Legal representative — Stable | 8 | 7 |
| Assessment by Parents/Legal representative — Improved | 6 | 10 |
| Assessment by Parents/Legal representative — Worsened | 5 | 1 |
Number of patients with at least one PAH-worsening component (death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH, new/worsening right heart failure) reported cumulatively over FUTURE 3 core and extension study.
| Participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| At least one PAH-worsening event | 10 | 5 |
| No PAH-worsening event | 23 | 26 |
PAH progression was defined by time elapsed from the first study drug administration in the FUTURE core study to the day of the first occurrence of any of the following PAH worsening events: death, lung transplant, hospitalization due to PAH progression, initiation of new therapy for PAH or new / worsening right heart failure. Subjects without a PAH worsening event were censored at EOT + 7 days. PAH progression was estimated by Kaplan-Meier methodology and expressed by the percentage of participants free of events at different time points.
| Percentage of patients free of events | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Kaplan-Meier estimate at Month 12 | 74.9 (56.0 to 86.6) | 88.9 (69.4 to 96.3) |
| Kaplan-Meier estimate at Month 18 | 68.2 (48.9 to 81.5) | 81.0 (60.1 to 91.7) |
Overall survival was defined as the time elapsed between the first study drug administration and death (any cause) up to end of study (Month 18 survival follow-up), regardless of whether the patient was on study treatment. Patients who died, regardless of the cause of death, were considered to have had an event. Patients last known to have been alive were censored on their date of last contact. Percentage of participants without death at different time points was estimated using Kaplan-Meier methodology.
| Percentage of participants | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. |
|---|---|---|
| Kaplan-Meier estimate at Month 12 | 81.8 (63.9 to 91.4) | 90.0 (72.1 to 96.7) |
| Kaplan-Meier estimate at Month 18 | 75.8 (57.3 to 87.1) | 86.5 (68.0 to 94.7) |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| Exceptional Use Treatment Period (EUTP): Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) up to 7 Days After Permanent Discontinuation of Study Drug | 80 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 7 Days After Permanent Discontinuation of Study Drug | 40 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Percentage of participants with AEs leading to premature discontinuation of study drug were reported.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With AEs Leading to Premature Discontinuation of Study Drug | 0 |
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With SAEs From 7 up to 60 Days After Permanent Discontinuation of Study Drug | 0 |
Percentage of participants with deaths were reported.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With Deaths | 10 |
Percentage of participants with AESI including liver abnormalities and anemia were reported.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With Adverse Events of Special Interest (AESI) | 20 |
Percentage of participants with treatment-emergent marked laboratory abnormalities were reported.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With Treatment-emergent Marked Laboratory Abnormalities up to 7 Days After Permanent Discontinuation of Study Drug | 0 |
Percentage of participants with liver function abnormalities: Alanine aminotransferase (ALT) greater than (\>)3\*upper limit of normal (ULN), ALT/aspartate aminotransferase (AST) \>3\*ULN, ALT /AST \>3\*ULN and less than or equal to (\<=) 5\*ULN, ALT/AST \>5\*ULN and \<=8\*ULN, ALT/AST \>8\*ULN and ALT/AST \>3\*ULN, total bilirubin \>2\*ULN and alkaline phosphatase (ALP) \<=2\*ULN were reported.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| EUTP: Percentage of Participants With Liver Function Abnormalities | 0 |
Percentage of participants with any time occurrence of hemoglobin (Hgb) less than or equal to (\<=) 10 g/dL and 8 g/dL between baseline and up to the last day of treatment + 7 days during EUTP were reported. Here "N" (number of subjects analyzed) signifies subjects who were evaluable for this outcome measure.
| percentage of participants | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|
| Hgb <=10 g/dL | 22.2 |
| Hgb <=8 g/dL | 0 |
Collected over From baseline up to end of treatment (and up to additional 60 days for serious adverse events and deaths), i.e. an average of 62 weeks and for EUTP: up to 7 days after discontinuation of study drug (approximately 3 years and 4 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan 2mg/kg b.i.d. | 8/33 (24.2%) | 15/33 (45.5%) | 24/33 (72.7%) |
| Bosentan 2mg/kg t.i.d | 4/31 (12.9%) | 13/31 (41.9%) | 23/31 (74.2%) |
| Bosentan 2mg/kg b.i.d or t.i.d. During EUTP | 1/10 (10%) | 4/10 (40%) | 8/10 (80%) |
| Event | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|---|---|
| PULMONARY HYPERTENSIVE CRISISRespiratory, thoracic and mediastinal disorders | 0/33 | 1/31 | 2/10 |
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 4/33 | 2/31 | 0/10 |
| MIGRAINE WITH AURANervous system disorders | 1/33 | 0/31 | 1/10 |
| PNEUMONIAInfections and infestations | 1/33 | 3/31 | 1/10 |
| RESPIRATORY TRACT INFECTION VIRALInfections and infestations | 0/33 | 1/31 | 1/10 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/33 | 0/31 | 1/10 |
| BRONCHOPNEUMONIAInfections and infestations | 0/33 | 2/31 | 0/10 |
| SYNCOPENervous system disorders | 2/33 | 0/31 | 0/10 |
| ATRIAL SEPTAL DEFECT REPAIRSurgical and medical procedures | 0/33 | 1/31 | 0/10 |
| BODY TEMPERATURE INCREASEDInvestigations | 0/33 | 1/31 | 0/10 |
| Event | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d | Bosentan 2mg/kg b.i.d or t.i.d. During EUTP |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/33 | 13/31 | 2/10 |
| PYREXIAGeneral disorders | 5/33 | 7/31 | 3/10 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 4/33 | 3/31 | 2/10 |
| PNEUMONIAInfections and infestations | 0/33 | 0/31 | 2/10 |
| DIARRHOEAGastrointestinal disorders | 2/33 | 6/31 | 0/10 |
| VOMITINGGastrointestinal disorders | 4/33 | 6/31 | 0/10 |
| NASOPHARYNGITISInfections and infestations | 6/33 | 5/31 | 1/10 |
| COUGHRespiratory, thoracic and mediastinal disorders | 4/33 | 3/31 | 1/10 |
| BLOOD BILIRUBIN INCREASEDInvestigations | 2/33 | 1/31 | 1/10 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 0/33 | 3/31 | 1/10 |
| Age, Continuous(years) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| Mean | 4.5 ± 3.35 | 5.2 ± 3.81 | 4.8 ± 3.57 |
| Age, Customized(Participants) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| Age Categories as per protocol — Infants and toddlers (28 days-23 months) | 10 | 11 | 21 |
| Age Categories as per protocol — Children (2-11 years) | 23 | 20 | 43 |
| Sex: Female, Male(Participants) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| Female | 18 | 10 | 28 |
| Male | 15 | 21 | 36 |
| Race/Ethnicity, Customized(Participants) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| Race as per protocol — Caucasian/White | 25 | 23 | 48 |
| Race as per protocol — Black | 1 | 2 | 3 |
| Race as per protocol — Asian | 6 | 4 | 10 |
| Race as per protocol — Hispanic | 0 | 1 | 1 |
| Race as per protocol — Other | 1 | 1 | 2 |
| Pulmonary Arterial Hypertension (PAH) etiology(Participants) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| Idiopathic | 14 | 15 | 29 |
| Heritable | 2 | 0 | 2 |
| Congenital heart disease | 6 | 2 | 8 |
| Associated PAH (i.e.,PAH after surgery for CHD) | 11 | 13 | 24 |
| Missing | 0 | 1 | 1 |
| World Health Organization functional class (WHO FC)(Participants) | Bosentan 2mg/kg b.i.d. | Bosentan 2mg/kg t.i.d. | Total |
|---|---|---|---|
| FC I | 9 | 10 | 19 |
| FC II | 12 | 15 | 27 |
| FC III | 12 | 6 | 18 |
Ran from Mar 2011 to primary completion in Aug 2014, 41 months.
Results were first posted in Dec 2017, 3 years 3 months after primary completion. A results delay was requested in Feb 2016.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 41 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Pulmonary Arterial Hypertension →